Cobra Bio-manufacturing Share Discussion Threads

[dpmcq] 09/1/2007 07:32

Great results and back into profit!!!!!!!!!!!


Highlights

Financial:

* Turnover up 31% to #10.1m (FY 2005: #7.7m)

* Profit before tax for the financial year #0.2m (FY 2005: #0.4m loss)

* Earnings per share 1.4p (FY 2005: 1.7p loss)

* Operating cash inflow doubled to #1.2m (FY 2005: #0.6m)

* Cash at bank (including short term deposits) increased to #3.2m
(30 Sept 2005: #3.0m)


Operational:

* North American turnover up 41% to #8.7m (FY 2005: #6.1m)

* Turnover from protein based products doubled to #6.7m (FY 2005: #3.2m)

* Jan 2007: Contracted order book for FY 2007 up 20% at #6.0m
(Jan 2006: #5.0m)

[robward] 05/1/2007 15:16

I DOUBT IT

[skyship] 05/1/2007 15:15

Finals due next Tuesday (9th Jan.) & hallelujah - some genuine buying today. could we see a second tick up ahead of the close??

[hyper al] 30/12/2006 10:49

fullupfool

"a good thing"

Not sure about that, the quotes that leedslad001 posted do sound very negative.

Although I'm sure Cobra will bounce back with some good news to counter the bad.

[fullupfool] 08/12/2006 09:34

Maybe its a good thing, from what i understand, the oxford plant is near full capacity. Saves having to ask for more cash to fund expansion, would be nice if the expansion was organic.

[leedslad001] 07/12/2006 17:22

Sold out today because of the info i found other day and today and the directors not bothering to answer my e-mail.
News below

Auxilium Pharmaceuticals Amends Agreement with Cobra Biologics Ltd.
Horsham Facility to Become Primary Commercial Source of AA4500

Development Relationship with Cobra Continues
MALVERN, Pa., Nov. 29 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced that it has amended its manufacturing agreement with UK-based Cobra Biologics Ltd. Under the amended agreement, Cobra will complete only one BLA (Biologics License Application) batch of the active ingredient for AA4500, the Company's injectable enzyme. The amendment reflects Auxilium's decision to move forward with its facility in Horsham, Pennsylvania to support the BLA submission and as a primary source of the commercial supply of AA4500. As previously announced, Auxilium will use the materials produced by Cobra in its ongoing and potential future clinical trials for AA4500 for the treatment of Dupuytren's contracture and other indications. The companies agreed to continue their collaboration related to the technology transfer, ongoing stability programs and other services provided by Cobra.
"This amendment allows our Manufacturing, Quality Assurance and Development teams to focus on getting the Horsham facility ready for the BLA submission expected at the end of 2007," said Mr. Armando Anido, Auxilium's Chief Executive Officer and President. "The amendment also ensures that Cobra will continue to provide technology support and be involved as a development partner for this critical asset. We look forward to continuing our collaboration with the Cobra team."

Auxilium Pharmaceuticals, Inc. Temporarily Suspends Dosing in Phase III Trials for AA4500 in Dupuytren's Contracture
Clinical Trial Material Fails Visual Appearance Test Conference Call Scheduled for 9:00 AM EST Thursday, December 7, 2006
MALVERN, Pa., Dec. 6 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that it has temporarily suspended the dosing of patients in the Company's ongoing phase III trials for AA4500 for the treatment of Dupuytren's contracture in response to a visual appearance failure of the lyophilized material in some vials of AA4500 for use in the clinical trials. The Company is conducting an investigation to determine the root cause of this failure and believes that it is likely related to the higher than expected moisture content within the vial. Based on tests conducted, the Company has excluded container closure as a cause and believes that the issue is related to the lyophilization process and/or equipment. The issue was identified as part of routine ongoing stability testing. The Company will hold a conference call to discuss this matter on December 7, 2006 at 9:00 a.m. Eastern Time.
The Company stated that it has not received any reports of adverse reactions from the ongoing phase III trials and that the clinical trial investigators would continue to monitor patients already dosed in accordance with the trial protocols.
"While we are disappointed by this development, we believe this is the right thing to do both for patients and for the Company, who have a common interest in successfully developing non-surgical therapies to effectively treat Dupuytren's contracture," said Mr. Armando Anido, Chief Executive Officer and President. "We know that the manufacture of biologics is complex and our team of experts will endeavor to complete the root cause investigation as soon as possible in order to implement corrective actions so that we can resume the phase III trials."
Both the U.S. and ex-U.S. studies are double-blind, randomized, placebo controlled studies of AA4500. The U.S. study is designed to enroll more than 200 patients at up to 15 sites, and the ex-U.S. study is designed to enroll up to 60 patients at sites in Australia and Switzerland.

[alibongo612] 06/12/2006 22:31

As I have said before their shareholdings are pathetic and demonstrate total lack of confidence in their own ability.

[leedslad001] 05/12/2006 18:38

You cant use outlook express as you would know excatly just what you can do.

As i said i hold 7k worth

[leedslad001] 05/12/2006 18:04

Have a look at MDW that is where my money has gone.
News to appear any day now. DYOR
As for MBO the directors at present time don't have much exposer to share price as their holdings are pathetic.
in contrast MDW directors hold 26% and put their money where thier mouth is.
I would take 62p as well

[leedslad001] 05/12/2006 17:46

fullupfool
have you never used e-mail tracking? this tells you when an e-mail has been read or deleted?
I still hold 7K worth
dave

[skyship] 05/12/2006 16:40

Ali - any MBO would obviously be at a reasonable premium to the current share price of 46p. A 35% premium @ 62p would get my vote. I suspect the finals on 9th Jan'07 will reveal the true value this stock now offers, so we should win either way.

The question for me is whether to top-up and go overweight in yet another AIM stock!? Have already done so in FIO & SGD - another two with improving Fundamentals but too small for institutional interest. Both are bid/MBO prospects IMO.

[fullupfool] 05/12/2006 10:53

Lol - complete idiot, there is no way of telling if an email has been deleted.

Oh, his last post was a deramp, shame if this spikes north now the results date have been announced and lee is without stock

[leedslad001] 30/11/2006 17:18

I tried e-mailing the company today, The ignorant people deleted my e- mail without even opening it. NOT the kind of directors i like to invest in!!! so i will reconsider my investment.
Dave

[alibongo612] 29/11/2006 18:22

If these ba*tards attempt an MBO at this price I for one will lobby hard to ensure it never happens.

[skyship] 29/11/2006 14:43

Intriguing sale of 40000 @ the Bid of 45.5p. Surely in normal circumstances any MM would only offer, say 43p, max 44p for that size. Must be a buyer in the background....As I've said before, I believe an MBO or a sale of this Company to the USA is an inevitability....just a matter of timing and price!

[fullupfool] 23/11/2006 17:25

well leeds chap - certainly know not to ever trust you again

[leedslad001] 23/11/2006 17:22

My bit of deramping didn't seem to work. So Bought 14K worth today :-)
Now lets see a move north to results and profitability.
Good luck all
dave

[terryjward] 22/11/2006 10:18

Looks like some expansion may be going on at Cobra, they are advertising for at least eleven new staff at Oxford and Keele in the November 18th issue of New Scientist. Note use of plural/singular for the production scientist posts.

OXFORD:
Team Leader Microbiology,
Microbiologist,
QA Officer,
QC Analytical Scientist,
Team Leader Upstream Processing,
Team Leader Downstream Processing,
Senior Production Scientist(s),
Production Scientists(s).

KEELE FACILITY:
QC Team Leader,
GMP Production Supervisor for Microbial fermentation,
Senior Research Molecular Biologist.

[leedslad001] 21/11/2006 17:40

Looks like this is going down further, A few sells most days.
Does people expect a cash call sooner than later?
My guess 35-40p the way this is going.
Any thoughts